Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03027232
Other study ID # 2007P000215
Secondary ID
Status Completed
Phase
First received January 13, 2017
Last updated April 26, 2018
Start date January 2007
Est. completion date December 15, 2017

Study information

Verified date April 2018
Source Beth Israel Deaconess Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The protocol is to draw peripheral blood from healthy volunteers for in vitro studies. The aims of these in vitro studies are to determine the cellular and intracellular mechanisms by which hypertonic saline and ATP release regulate neutrophil and lymphocyte functions.


Description:

The proper regulation of leukocyte function is critical for immune defense and to prevent autoimmune diseases. Many aspects of immune cell regulation are unknown. A better understanding could lead to novel therapeutic approaches to improve immune function in patients suffering from various diseases.

The investigators have found that hypertonic conditions regulate leukocyte functions through feedback mechanisms involving ATP release and purinergic receptors. The purpose of the proposed protocol is to obtain access to peripheral blood from healthy volunteers to study these complex regulatory mechanisms in more detail.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date December 15, 2017
Est. primary completion date December 15, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- any healthy volunteer

Exclusion Criteria:

- pregnancy

- needing/using drugs

- inflammatory or infectious complications

Study Design


Related Conditions & MeSH terms


Intervention

Other:
No intervention (drugs) will be given. Purpose: collecting blood for in vitro studies
No drugs or interventions are given. Single purpose is to draw blood from healthy subjects to study immune cell biology in vitro. No records about subjects to be kept.

Locations

Country Name City State
United States BIDMC Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Beth Israel Deaconess Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Immune cells will be studied in vitro to learn about basic mechanisms of immune cell signaling. The purpose of this study is to obtain blood from healthy subjects (volunteers) for in vitro studies to explore how immune cells function. Cells will be isolated and subjected to various tests including stimuli that simulate immune cell activation in health and disease. Subjects will not be subjected to any treatments. Only some of the cells (leukocytes) in the blood will be studied. For example, activation events such as cytokine production, the ability of leukocytes (=immune cells) to detect and respond to bacterial products will be assessed. No identifiable information about study subjects will be kept. Blood is collected as needed; time frame: indefinitely. Blood used between 1-7 days after blood draws.
See also
  Status Clinical Trial Phase
Completed NCT03242395 - PRIME: Cognitive Outcome Following Major Burns N/A
Recruiting NCT04032626 - MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients Phase 2
Completed NCT04002219 - Efficacy Evaluation of the Mushroom Beverage on Emotion Regulation N/A
Not yet recruiting NCT06177028 - MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease Phase 2
Active, not recruiting NCT05515640 - Dysautonomia and Systemic Interactions in Traumatic Brain Injury